



# Iowa Department of Human Services

Terry E. Branstad  
Governor

Kim Reynolds  
Lt. Governor

Charles M. Palmer  
Director

## Iowa Medicaid Drug Utilization Review (DUR) Commission Meeting

December 7, 2011

**Location: Learning Resource Center  
Fairmeadows Conference Room  
3550 Mills Civic Parkway  
West Des Moines, Iowa**

**Time: 9:30 a.m. – 1:30 p.m.**

### Final Agenda

1. Welcome & Introductions
  - a) Commission Members and Staff
  - b) Approval of the Minutes
2. Iowa Medicaid Enterprise Update(s)
3. Prevalence Report Summary
4. Case Studies
5. Sucralfate (*Carafate*) Suspension Utilization
6. Public Comment (See Conflict of Interest Disclosure Form)
7. Lost, Stolen, Destroyed Medication Overrides
8. ProDUR Edits
  - a) Sinecatechins (*Veregen*<sup>®</sup>)
  - b) Letrozole (*Femara*)
9. Prior Authorization
  - a) Nebivolol (*Bystolic*<sup>®</sup>) – Initial Review
  - b) Vilazodone (*Viibryd*<sup>™</sup>) – Initial Review
  - c) Anti-Acne PA –Second Review
  - d) Topical Retinoids – Second Review
  - e) Dextromethorphan/Quinidine (*Nuedexta*<sup>™</sup>) – Second Review
  - f) Roflumilast (*Daliresp*<sup>™</sup>) –Second Review
10. Psychotropic Medications in Children
  - a) Department of Health & Human Services Letter

- b) Atypical Antipsychotic Tip Sheet for Pediatric Use
- 11. Public Comment (See Conflict of Interest Disclosure Form)
- 12. Focus Studies/Provider Education Initiatives
  - a) Chronic Mupirocin – Follow Up
  - b) Chronic Triptans – Follow Up
  - c) Chronic Use of Skeletal Muscle Relaxants – Initial Review
  - d) High Dose Citalopram – Initial Review
  - e) Quetiapine and QT Prolongation – Initial Review
  - f) Simvastatin High Dose & Drug Interactions – Initial Review
- 13. Miscellaneous
  - a) DUR Digest Vol. 24, No. 2
  - b) SMAC Update
  - c) MedWatch
- 14. Executive Closed Session
  - a) Approval of Minutes
  - b) Prevalence Report - Top 100 Providers by Dollar Amount and Script Count
  - c) Lost, Stolen, Destroyed Medications – Review of Overrides
  - d) Member Profiles
- 15. Adjournment

Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted twice during the open portion of the meeting. In order to accommodate all interested parties, all speakers are requested to limit their comments to **5 minutes or less**. If you represent a drug manufacturer as an employee, as a contractor, as a member of the manufacturer's Speaker Bureau, or by any other means, we expect you to cover your individual product or entire product line in that five-minute time frame. Speakers who represent multiple manufacturers will share their 5 minutes with the other manufacturer representative(s) whose product they are speaking on.

**[www.iadur.org](http://www.iadur.org)**

For more information contact the DUR Project Coordinator, Pam Smith, R.Ph., at [info@iadur.org](mailto:info@iadur.org) or (515) 974-3131

**\*\*\*Next Meeting February 2, 2012\*\*\*  
At the Learning Resource Center in West Des Moines**